Showing 1761-1770 of 10612 results for "".
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingPivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingRAS Across Tumors: Who to Test When
https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
https://reachmd.com/programs/cme/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingEvaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/Review clinical features, diagnostic criteria, and treatment options for PBC, a chronic liver disease primarily affecting women over age 50.Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
https://reachmd.com/programs/cme/diagnostic-and-diagnosis-logistics-navigating-complexity-across-ages/39028/Tune in to explore age-related diagnostic considerations and confirmation strategies for generalized myasthenia gravis.NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.